Search

Your search keyword '"Laufer, Rachel S."' showing total 11 results
Start Over Author "Laufer, Rachel S."
11 results on '"Laufer, Rachel S."'

1. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

Author

Fitzpatrick, Meagan C., primary, Laufer, Rachel S., additional, Baral, Ranju, additional, Driscoll, Amanda J., additional, Feikin, Daniel R., additional, Fleming, Jessica A., additional, Jit, Mark, additional, Kim, Sonnie, additional, Koltai, Mihaly, additional, Li, You, additional, Li, Xiao, additional, Nair, Harish, additional, Neuzil, Kathleen M., additional, Pecenka, Clint, additional, Sparrow, Erin, additional, Srikantiah, Padmini, additional, and Ortiz, Justin R., additional

Published
2023
Full Text
View/download PDF

2. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis

Author

Laufer, Rachel S., primary, Baral, Ranju, additional, Buchwald, Andrea G., additional, Campbell, James D., additional, Coulibaly, Flanon, additional, Diallo, Fatoumata, additional, Doumbia, Moussa, additional, Driscoll, Amanda J., additional, Galvani, Alison P., additional, Keita, Adama M., additional, Neuzil, Kathleen M., additional, Sow, Samba, additional, Pecenka, Clint, additional, Ortiz, Justin R., additional, and Fitzpatrick, Meagan C., additional

Published
2023
Full Text
View/download PDF

3. Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence

Author

Ortiz, Justin R., primary, Laufer, Rachel S., additional, Brunwasser, Steven M., additional, Coulibaly, Flanon, additional, Diallo, Fatoumata, additional, Doumbia, Moussa, additional, Driscoll, Amanda J., additional, Fell, Deshayne B., additional, Haidara, Fadima C., additional, Hartert, Tina V., additional, Keita, Adama M., additional, Neuzil, Kathleen M., additional, Snyder, Brittney M., additional, Sow, Samba, additional, and Fitzpatrick, Meagan C., additional

Published
2023
Full Text
View/download PDF

4. Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis

Author

Laufer, Rachel S, primary, Baral, Ranju, additional, Buchwald, Andrea G, additional, Campbell, James D, additional, Coulibaly, Flanon, additional, Diallo, Fatoumata, additional, Doumbia, Moussa, additional, Driscoll, Amanda J, additional, Galvani, Alison P, additional, Keita, Adama S, additional, Neuzil, Kathleen M, additional, Sow, Samba, additional, Pecenka, Clint, additional, Ortiz, Justin R, additional, and Fitzpatrick, Meagan C, additional

Published
2022
Full Text
View/download PDF

5. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions

Author

Laufer, Rachel S., primary, Driscoll, Amanda J., additional, Baral, Ranju, additional, Buchwald, Andrea G., additional, Campbell, James D., additional, Coulibaly, Flanon, additional, Diallo, Fatoumata, additional, Doumbia, Moussa, additional, Galvani, Alison P., additional, Haidara, Fadima C., additional, Kotloff, Karen L., additional, Keita, Adama M., additional, Neuzil, Kathleen M., additional, Orenstein, Evan W., additional, Orenstein, Lauren A.V., additional, Pecenka, Clint, additional, Sow, Samba, additional, Tapia, Milagritos D., additional, Ortiz, Justin R., additional, and Fitzpatrick, Meagan C., additional

Published
2021
Full Text
View/download PDF

6. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa

Author

Hegerle, Nicolas, primary, Choi, Myeongjin, additional, Sinclair, James, additional, Amin, Mohammed N., additional, Ollivault-Shiflett, Morgane, additional, Curtis, Brittany, additional, Laufer, Rachel S., additional, Shridhar, Surekha, additional, Brammer, Jerod, additional, Toapanta, Franklin R., additional, Holder, Ian Alan, additional, Pasetti, Marcela F., additional, Lees, Andrew, additional, Tennant, Sharon M., additional, Cross, Alan S., additional, and Simon, Raphael, additional

Published
2018
Full Text
View/download PDF

7. Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa

Author

Baliban, Scott M., primary, Yang, Mingjun, additional, Ramachandran, Girish, additional, Curtis, Brittany, additional, Shridhar, Surekha, additional, Laufer, Rachel S., additional, Wang, Jin Y., additional, Van Druff, John, additional, Higginson, Ellen E., additional, Hegerle, Nicolas, additional, Varney, Kristen M., additional, Galen, James E., additional, Tennant, Sharon M., additional, Lees, Andrew, additional, MacKerell, Alexander D., additional, Levine, Myron M., additional, and Simon, Raphael, additional

Published
2017
Full Text
View/download PDF

10. Effect of Analgesics on Monoclonal Antibody Ascites Production in Mice Administered Upon Recognition of Pain.

Author

Marko, Shannon T., Little, Stephen F., Benton, Carrie G., Kelly III, Richard, Field, Amy E., and Laufer, Rachel S.

Subjects
PHYSIOLOGICAL effects of analgesics, MONOCLONAL antibodies, LABORATORY mice, DRUG administration, ANTIBODY titer, PAIN management, ASCITES
Abstract

Monoclonal antibody (mAb) ascites fluid production in mice is a well described method of antibody production, although ethical questions regarding the pain and distress of the animals utilized in this process have been raised. In this study, mice were injected with pristane to initiate granuloma formation, followed by an injection of murine hybridoma PA 2II 2F9-1-1 (2F9) to produce IgG1 subclass mAb directed against protective antigen (PA) protein of Bacillus anthracis. Upon the recognition of pain or distress, characterized by well accepted clinical signs, analgesics were administered by treatment group.The control group (A) received saline, group (B) received meloxicam, group (C) received buprenorphine, and group (D) received both meloxicam and buprenorphine. Analgesics were administered by group for a total of 36-48 hours prior to the second ascites fluid collection. There was no statistical difference in the antibody titer or functionality (P > 0.05) between treatment groups at the first or the second collection time points. As reported here, analgesics may be administered upon recognition of pain in mice used for mAb ascites fluid production without affecting antibody concentration or quality and may warrant further evaluation as a refinement in other hybridoma cell lines. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results